NCT04480099 is a Phase 2 clinical trial of CHOP in Peripheral T-cell Lymphoma, sponsored by Ruijin Hospital.

Who is sponsoring NCT04480099?

NCT04480099 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT04480099?

Interventions in NCT04480099: CHOP, CHOP+X.

What condition does NCT04480099 study?

NCT04480099 studies Peripheral T-cell Lymphoma.

Is NCT04480099 still recruiting?

NCT04480099 is currently status unknown. Last updated 10 June 2023.

Last reviewed 2023-06-10 · How we verify

NCT04480099

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy and Safety of Targeted Drug in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma

Status unknown Phase 2 Last updated 10 June 2023

What this trial tests

Phase 2 trial testing CHOP in Peripheral T-cell Lymphoma in 96 participants. Status unknown.

Timeline

29 July 2020

Primary endpoint
20 April 2023

1 April 2024

Quick facts

Lead sponsor	Ruijin Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	96
Start date	29 July 2020
Primary completion	20 April 2023
Estimated completion	1 April 2024
Sites	7 locations across China

Drugs / interventions tested

CHOP (CHOP) — full drug profile →
CHOP+X — full drug profile →

Conditions studied

Peripheral T-cell Lymphoma — all drugs for Peripheral T-cell Lymphoma →

Sponsor

Ruijin Hospital

Who can join

18 and older, any sex, with Peripheral T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Complete response rate
Time frame: At the end of Cycle 6 (each cycle is 21 days)
Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria

Sponsor's own description

This prospective，multi-center，open-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914
Novel targeted therapies of T cell lymphomas.
Iżykowska K, Rassek K, Korsak D, Przybylski GK, et al · · 2020 · cited 49× · PMID 33384022 · DOI 10.1186/s13045-020-01006-w
Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.
Polgárová K, Otáhal P, Šálek C, Pytlík R. · · 2022 · cited 14× · PMID 35600381 · DOI 10.3389/fonc.2022.876758
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application.
Huang Z, Fu Y, Yang H, Zhou Y, et al · · 2024 · cited 10× · PMID 38365716 · DOI 10.1186/s12943-024-01947-7
The Status and Prospects of Epigenetics in the Treatment of Lymphoma.
Liu J, Li JN, Wu H, Liu P. · · 2022 · cited 10× · PMID 35463343 · DOI 10.3389/fonc.2022.874645
Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial.
Cai MC, Cheng S, Jing HM, Liu Y, et al · · 2024 · cited 5× · PMID 39175480 · DOI 10.1016/j.lanwpc.2024.101160

Verify or expand the search:

Other trials of CHOP

Trials testing the same drug.

NCT06961500 — Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Gra · Phase 2 · not yet recruiting
NCT04745832 — Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) · Phase 3 · terminated
NCT04243434 — PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients · Phase 1 · unknown
NCT04002947 — Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma · Phase 2 · recruiting
NCT03145480 — Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients · Phase 2 · terminated

Other recruiting trials for Peripheral T-cell Lymphoma

Currently open trials in the same condition.

NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
NCT06914037 — A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies · Phase 1 · recruiting
NCT07072221 — Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients · NA · recruiting
NCT06739265 — Golidocitinib Plus CHOP in Newly Diagnosed PTCL · Phase 1, PHASE2 · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04480099 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 10 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04480099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing